A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms

Clinical Therapeutics

Volumn 28, Issue 2, 2006, Pages 204-221

  Williams, Gary W ^a   Kivitz, Alan J ^b   Brown, Mark T ^c   Verburg, Kenneth M ^c  

^a SCRIPPS CLINIC   (United States)

^b Altoona Center for Clinical Research   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; VALDECOXIB;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENDOCARDIAL DISEASE; EVALUATION; FEMALE; FLATULENCE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ANEURYSM; HUMAN; HYPERTENSION; LABORATORY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOCARDIAL DISEASE; NAUSEA; ONSET AGE; PALLIATIVE THERAPY; PARAMETERS OF MEASUREMENT AND ANALYSIS; PATIENT ASSESSMENT; PERICARDIAL DISEASE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PROSTATE DISEASE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH ULCER; SYMPTOMATOLOGY; SYSTOLIC HYPERTENSION; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; VALVULAR HEART DISEASE; VITAL SIGN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRALGIA; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; NAPROXEN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33646201730     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.01.016     Document Type: Article

References (25)

1. Crofford L., Lipsky P., Brooks P., et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 43 (2000) 4-13
2. Dubois R., Abramson S., Crofford L., et al. Cyclooxygenase in biology and disease. FASEB J. 12 (1998) 1063-1073
3. Kivitz A., Eisen G., Zhao W., et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract. 51 (2002) 530-537
4. Makarowski W., Zhao W., Bevirt T., and Recker D. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: A randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 10 (2002) 290-296
5. Sikes D., Agrawal N., Zhao W., et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol. 14 (2002) 1101-1111
6. Goldstein J., Eisen G., Agrawal N., et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther. 20 (2004) 527-538
7. Eisen G., Goldstein J., Hanna D., and Rublee D. Meta-analysis: Upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment Pharmacol Ther. 21 (2005) 591-598
8. Rabeneck L., Goldstein J., Vu A., et al. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. Am J Gastroenterol. 100 (2005) 1043-1050
9. Bensen W., Weaver A., Espinoza L., et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: A randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford) 41 (2002) 1008-1016
10. Pavelka K., Recker D., and Verburg K. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: Results of a 26-week trial. Rheumatology (Oxford) 42 (2003) 1207-1215
11. Hippisley-Cox J., and Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 330 (2005) 1366
12. Johnsen S., Larsson H., Tarone R., et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study. Arch Intern Med. 165 (2005) 978-984
13. Nussmeier N., Whelton A., Brown M., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
14. White W., Strand V., Roberts R., and Whelton A. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther. 11 (2004) 244-250
15. for the Multicenter Study of Perioperative Ischemia (McSPI) Research Group and the Ischemia Research and Education Foundation (IREF) Investigators. Ott E., Nussmeier N., Duke P., et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125 (2003) 1481-1492
16. Whelton A., Nussmeier N., Martineau R., et al. Safety of parecoxib and valdecoxib in the treatment of postoperative pain following coronary artery bypass graft surgery or major general surgery. Presented at: American College of Cardiology Annual Scientific Session. Orlando, Fla (March 6-9, 2005)
17. Available at. Jenkins J., and Seligman P. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. Food and Drug Administration. Accessed June 20, 2005. http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf
18. Arnett F., Edworthy S., Bloch D., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
19. Hochberg M., Chang R., Dwosh I., et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 35 (1992) 498-502
20. (Suppl). Fries J. The assessment of disability: From first to future principles. Br J Rheumatol 22 (1983) 48-58
21. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988) 800-802
22. (Suppl). Whelton A., White W., Kent J., and Verburg K. Hypertension and edema rates in 6,717 patients for the new COX-2 inhibitor valdecoxib versus the conventional, nonselective NSAIDs and placebo (P-446). Abstract. Am J Hypertens 16 (2003) 199A
23. [published correction appears in Am J Ther. 2000; 7:341]. Whelton A., Maurath C., Verburg K., and Geis G. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 7 (2000) 159-175
24. Whelton A. COX-2-specific inhibitors and the kidney: Effect on hypertension and oedema. J Hypertens Suppl. 20 (2002) S31-S35
25. (Suppl). Williams G., White W., Moore R., et al. Cardiovascular safety of valdecoxib: A meta-analysis of 19 clinical studies in 12,000 patients. Arthritis Rheum. 52 (2005) S406